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Background: Tumour-infiltrating lymphocytes (TILs) have been shown to predict survival in numerous
malignancies. The importance of TILs in primary pancreatic neuroendocrine tumours (NETs) and NET liver
metastases (NETLMs) has not been defined.
Methods: We identified 87 patients with NETs and 39 with NETLMs who had undergone resection.
Immunohistochemistry was performed to determine TIL counts. Recurrence-free survival (RFS) and
overall survival (OS) were determined using the log-rank test.
Results: The median follow-up time was 62 months in NET patients and 48 months in NETLM patients.
Vascular invasion and histologic grade were the only independent predictors of outcome for NETs and
NETLMs, respectively. Analysis of intermediate-grade NETs indicated that a dense T cell (CD3+) infiltrate
was associated with a median RFS of 128 months compared with 61 months for those with low levels of
intratumoral T cells (P = 0.05, univariate analysis). Examination of NETLMs revealed that a low level of
infiltrating regulatory T cells (Treg, FoxP3+) was a predictor of prolonged survival (P < 0.01, univariate
analysis).
Conclusions: A robust T cell infiltrate is associated with improved RFS following resection of
intermediate-grade NETs, whereas the presence of more Treg correlated with shorter OS after treatment
of NETLMs. Further study of the immune response to intermediate-grade NETs and NETLMs is warranted.
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Introduction
Well-differentiated pancreatic neuroendocrine tumours (NETs)
are rare and manifest with a broad spectrum of biologic behav-
iour. Annual incidence in the USA amounts to four cases per
million people and survival rates at 5 years have been reported to
range from 44% to 71%.1–4 Neuroendocrine tumour liver
metastases (NETLMs) are a frequent cause of death in patients
with pancreatic or gastrointestinal NETs.5 Despite median sur-
vival times of 81–96 months in patients selected for surgical resec-
tion of NETLMs, the majority suffer from recurrent or progressive
disease.6–8 Numerous correlates of outcome following resection of
NETs and NETLMs, including histologic grade, surgical margin
status, vascular invasion, tumour size and the presence of
metastases, have been described.9–14 Among prognostic factors for
NETs and NETLMs, histologic grade, as determined by the mitotic
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rate and presence of necrosis, has been shown to be a powerful
surrogate for tumour biology and patient outcome.6,10,12 Despite
the identification of important prognostic factors for NETs and
NETLMs, coping with the marked degree of biologic heterogene-
ity in attempting to determine prognosis or optimal treatment
remains challenging.15
Tumour-infiltrating lymphocytes (TILs) have been shown to
predict outcome in patients with hepatocellular carcinoma,16,17
colorectal cancer,18–21 and ovarian cancer.22 Although the prognos-
tic importance of TILs in numerous human malignancies has
been documented, the utility of TILs for risk stratifying individu-
als with neuroendocrine neoplasia is unclear. The rarity of NETs
and the generally favourable prognosis for those patients with
low-grade tumours are likely explanations for the paucity of data
with respect to the impact of TILs on this disease. Yet, prognoses
for patients with intermediate-grade NETs or those with NETLMs
vary considerably. Study of the host immune response may enable
the identification of patients at elevated risk for recurrence fol-
lowing treatment and the selection of patients most likely to expe-
rience prolonged survival following aggressive intervention. The
present study was designed to determine the potential prognostic
importance of TILs in NETs and NETLMs.
Materials and methods
Patients and clinical variables
With the approval of the institutional review board and in accor-
dance with Health Insurance Portability and Accountability Act
regulations, a prospectively maintained database was used. We
identified 87 patients with NETs and 39 with NETLMs who
underwent resection at the Memorial Sloan-Kettering Cancer
Center (MSKCC), New York, during 1992–2004 and from whom
tissue adequate for analysis was available. Clinicopathologic data
on the patients in this study have been previously reported.10,12
Only three patients overlapped between the NET and NETLM
datasets. Given the rarity of NETs and NETLMs, we included
NETLMs from various primary sites.
Pathologic variables and immunohistochemistry
After review of the archived primary tumour haematoxylin and
eosin (H&E) slides and diagnostic confirmation, sections were
deparaffinized, rehydrated in graded alcohol, and processed as
previously described.23 Monoclonal antibodies were used to detect
CD3 (F7.2.38; Dako North America, Inc., Carpinteria, CA, USA),
CD8 (c8/144B; Dako North America, Inc.), FoxP3 (236A/E7;
Abcam, Inc., Cambridge, MA, USA) and CD4 (polyclonal goat;
R&D Systems, Inc., Minneapolis, MN, USA). Appropriate positive
controls were used. Samples were then incubated with biotiny-
lated anti-mouse immunoglobulins at a dilution of 1:500 (Vector
Laboratories, Inc., Burlingame, CA, USA), followed by avidin–
biotin peroxidase complexes (1:25; Vector Laboratories, Inc.) for
30 min. Diaminobenzidine was used as the chromagen and
haematoxylin was used as the nuclear counter stain.
Tumours were assigned a histologic grade on the basis of
mitotic figure count and degree of tumour necrosis.10,12 Tumour-
infiltrating lymphocytes were counted and scored by a single
pathologist (LHT) on a scale of 0–3 based on cell density within
the tumours. Scores were based on the following criteria: grade 0
1+
2+
3+
Figure 1 Neuroendocrine tumours were stained with anti-CD3 to
identify infiltrating T cells. Grading levels were assigned according to
the following criteria per 10 highpower fields: grade 0 = < 10 cells;
grade 1 = < 1% or 10–20 cells; grade 2 = 1–5% or 21–50 cells, and
grade 3 = > 5% or >50 cells. (Haematoxylin and eosin stain; original
magnification 400¥)
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Table 1 Clinicopathologic variables in primary pancreatic neuroendocrine tumours
All Low grade Intermediate grade P-value
Age, years
Median 56 64 53 0.04
Range 19–85
Gender
Male 46% 40% 56% 0.12
Female 54% 60% 44%
Tumour sizea
4.2 cm 46% 42% 53% 0.09
<4.2 cm 54% 58% 47%
Surgical margin
Positive 15% 8% 23% 0.07
Negative 85% 92% 77%
Vascular invasion
Present 46% 31% 68% 0.001
Absent 54% 69% 32%
Functional
Yes 14% 17% 8% 0.25
No 86% 83% 92%
Gradeb
Intermediate 43% – – –
Low 54%
Pancreatic resection
Enucleation 13% 17% 8% 0.41
Distal pancreatectomy 54% 50% 61%
Pancreaticoduodenectomy 33% 33% 31%
Lymph node sampling
Yes 70% 71% 72% 0.84
No 30% 29% 28%
Lymph node metastases
Present 27% 20% 39% 0.13
Absent 73% 80% 61%
Synchronous liver metastases
Present 16% 6% 29% 0.01
Absent 84% 94% 71%
CD3
High (1–3) 68% 75% 64% 0.19
Low (0) 32% 25% 36%
CD4
High (1–3) 65% 64% 69% 0.76
Low (0) 35% 36% 31%
CD8
High (0–1) 45% 49% 44% 0.54
Low (2–3) 55% 51% 56%
FoxP3
High (1–3) 34% 33% 36% 0.25
Low (0) 66% 67% 64%
aMedian tumour size was 4.2 cm
b3% were high grade
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= < 10 cells per 10 highpower fields (hpf); grade 1 = < 1% or 10–20
cells per 10 hpf; grade 2 = 1–5% or 21–50 cells per 10 hpf, and
grade 3 = > 5% or > 50 cells per 10 hpf (Fig. 1). Cut-off points for
analyses were assigned based upon the median score for each
marker. We counted intratumoral T cells only, as representative
sections of the interface between tumour and normal tissue were
not uniformly present, an approach that had been previously
validated.18
Statistical analysis
A two-sample t-test was used to compare the distribution of con-
tinuous variables across groups when the distribution was reason-
ably symmetric. When the variables to be compared had skewed
distributions, the Mann–Whitney U-test was used. The chi-
squared test was used for categorical variables. The date of disease
recurrence was defined as the date of earliest radiographic evi-
dence of new tumour formation. Overall survival (OS) and
recurrence-free survival (RFS) probabilities were estimated using
the Kaplan–Meier method. Univariate associations were assessed
using the log-rank test; variables with P  0.05 on univariate
analysis were included by multivariate analysis using a Cox model.
Statistical analyses were performed using spss Version 15.0 (SPSS,
Inc., Chicago, IL, USA).
Results
Primary and metastatic tumour patient characteristics
and follow-up
We analysed 87 patients with primary NETs who underwent resec-
tion at MSKCC to determine if the degree of T cell infiltration
would correlate with either RFS or OS. The median follow-up for
the entire group was 62 months and the median RFS was 106
months; the median OS was not reached. The average age of the
group was 56 years (range: 19–85 years) and 46% of the patients
were male (Table 1). Intermediate- and low-grade tumours were
analysed separately to determine the biologic and immunologic
differences between the two groups. Those with intermediate-
grade tumours presented at a significantly younger age (median
age: 53 years) compared with patients with low-grade lesions
(median age: 64 years) (P = 0.04). Functional tumours were
present in 14% of the patients and tumour function did not
correlate with tumour grade. The majority of patients underwent
distal pancreatectomy (54%) or pancreaticoduodenectomy
(33%), as opposed to enucleation (13%). Intermediate-grade
tumours were significantly more likely to be associated with vas-
cular invasion (P = 0.001) or to present with synchronous liver
metastases (P = 0.01). Lymph node metastases were more
common among patients with intermediate-grade lesions, but this
was not significant (P = 0.13). Patients with nodal metastases were
significantly more likely to have larger primary tumours (P = 0.04)
when only those who underwent lymphadenectomy were
considered.
For the 39 patients with NETLMs, the median follow-up was 48
months and the median OS was 63 months. The average age of
Table 2 Clinicopathologic variables in neuroendocrine tumour liver
metastases
All
Age, years
Median 53
Range 25–84
Tumour size, cm
Median 8.5
Range 1.0–22.3
Tumour number
Median 2
Range 1–11
Gender
Male 13 (33%)
Female 26 (67%)
Margin
R0 11 (28%)
R1 11 (28%)
R2 15 (39%)
Grade
Low 19 (49%)
Intermediate 13 (33%)
High 7 (18%)
Primary site
Pancreas 11 (28%)
Small bowel 8 (21%)
Unknown 14 (36%)
Other 6 (15%)
Symptoms
Present 28 (72%)
Octreotide therapy
Yes 11 (28%)
Chemotherapy
Yes 10 (26%)
Embolization
Yes 15 (39%)
CD3
High (2–3) 23 (59%)
Low (0–1) 16 (41%)
CD4
High (3) 21 (54%)
Low (0–2) 18 (46%)
CD8
High (2–3) 22 (56%)
Low (0–1) 17 (44%)
FoxP3
High (1–3) 13 (33%)
Low (0) 26 (67%)
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patients with NETLMs was 53 years (range: 25–83 years) and 67%
were female (Table 2). Most patients were symptomatic, the
majority had bilateral NETLMs, and the pancreas was the most
common verified primary tumour site. The median liver tumour
size was 8.5 cm (range: 1.0–22.3 cm) and the median number of
liver metastases was two.
Degree of primary and metastatic tumour
lymphocyte infiltration
Immunohistochemical staining revealed that T cells (CD3+) infil-
trated the majority (68%) of NETs (Fig. 1). Only 34% of patients
were found to have FoxP3+ TILs, which are regulatory T cells
(Treg).24 Tumour grade did not correlate with the degree of lym-
phocytic infiltration when assessed with CD3, CD4, CD8 or FoxP3
(Table 1). Additionally, the degree of T cell infiltration was not
associated with any of the other clinicopathologic variables analy-
sed. The vast majority of patients with NETLMs (97%) had some
degree of T cell (CD3+) infiltration and Treg were detected in
33%. Potentially immunosuppressive Treg were present in 55% of
intermediate/high-grade tumours, whereas only 16% of low-
grade NETLMs demonstrated intratumoral Treg (P = 0.02).
Outcome following resection of primary NETs is
predicted by histologic features
In addition to determining the prognostic importance of TILs in
NETs, we analysed standard clinicopathologic correlates of
outcome in our selected patient group. Larger tumour size, nodal
metastases, vascular invasion, higher tumour grade and positive
surgical margins were predictors of RFS (Table 3). Among these
factors, vascular invasion was an independent predictor of disease
Table 3 Predictors of recurrence-free survival in neuroendocrine tumours
Variables Median RFS, months P-value Multivariate
RR (95% CI), P-value
Tumour sizea
4.2 cm 97 0.005 0.06
<4.2 cm 135
Lymph node metastasesb
Present 67 0.006 0.46
Absent 128
Vascular invasion
Present 72 <0.001 8.2 (1.8–37.0), 0.007
Absent NR
Gradec
Intermediate 65 0.02 0.61
Low 113
Surgical margin
Positive 66 0.007 0.50
Negative 128
CD3
High 99 0.52 –
Low 135
CD8
High 106 0.68 –
Low 113
CD4
High 99 0.53 –
Low 128
FoxP3
High 98 0.24 –
Low 116
aMedian tumour size was 4.2 cm
bOnly patients who underwent lymph node sampling were included
cIntermediate grade defined by 1 mitotic figure/50 highpower fields
RFS, recurrence-free survival; RR, relative risk; 95% CI, 95% confidence interval; NR, not reported
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recurrence (relative risk [RR] = 6.7,P = 0.05). T cell counts did not
correlate with recurrence following resection of NETs when the
entire patient group was analysed (Fig. 2).
T cell count predicts recurrence in
intermediate-grade NET
As discussed above, NETs encompass a broad spectrum of patho-
biology and tumour grade as determined by the mitotic rate and
presence of necrosis.10,12 A prior report demonstrated that NETs
can be stratified into biologically distinct groups on the basis of
grade.12 To determine the biologic relevance of TILs in NETs
among patients with more aggressive disease biology, we per-
formed separate analyses for patients with low- and intermediate-
grade tumours. Among patients with low-grade NETs, there was
no association between T cell infiltrates and outcome. However,
when analysing only those with intermediate-grade neoplasms,
the T cell infiltrate (CD3+ TILs) was a significant univariate pre-
dictor of recurrence following resection (Table 4, Fig. 3).
Treg predict outcome following resection of NETLMs
Having found that recurrence following resection of
intermediate-grade NETs correlated with the degree of T cell infil-
tration, we examined TILs in NETLMs, which are more likely to
originate from higher-grade primary tumours. Given that many
patients with NETLMs underwent debulking procedures for
symptoms and that the complete eradication of liver tumours was
not possible (Table 2), we chose OS instead of RFS as the endpoint
for our analysis of NETLMs. Histologic grade (Table 5) was a
significant, independent predictor of OS following resection of
NETLMs (P > 0.001). The degree of infiltration by CD3+, CD4+
or CD8+ TILs did not predict OS following treatment of
NETLMs. However, the presence of FoxP3+ cells or Treg within
NETLMs was significantly correlated with shorter OS times on
univariate analysis (P = 0.03).
Discussion
This is the largest study to date to assess the correlation between T
cell infiltration and outcome following resection of well-
differentiated pancreatic NETs and NETLMs. Consistent with a
prior report,25 we have demonstrated the presence of T cells
within the majority of NETs. The degree of T cell infiltration as
measured by CD3 staining was associated with RFS in patients
with intermediate-grade NETs. Although higher levels of CD4 and
CD8 T cell infiltration trended toward an association with
improved RFS in patients with intermediate-grade tumours, these
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Figure 2 Neuroendocrine tumours were stained with anti-CD3 (all T cells), anti-CD8 (cytotoxic T cells), anti-CD4 (helper T cells), and
anti-FoxP3 (regulatory T cells) to quantify the numbers of various T cell subsets within the tumours. Kaplan–Meier analyses were performed
to determine differences in recurrence-free survival among patients with high and low levels of T cell infiltration
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results were not statistically significant. A higher number of Treg
was associated with decreased survival following treatment of
NETLMs.
Tumour-infiltrating lymphocytes have been shown to predict
outcome in numerous primary human malignancies, including
melanoma, pancreatic adenocarcinoma, ovarian carcinoma, hepa-
tocellular carcinoma and colorectal cancer.18,20,21 Ryschich and col-
leagues reported that a moderate degree of T cell infiltration was
present in eight of 11 patients with NETs.25 Our interest in
NETLMs TILs was based upon our recent report demonstrating
the predictive power of intratumoral T cells following resection of
colorectal cancer liver metastases.20 We have confirmed that the
majority of NETs and NETLMs are infiltrated by T cells. In the
present study, 68% of patients with NETs and 97% of those with
NETLMs were found to have T cells within their tumours
(Tables 1 and 2). The degree of NET T cell infiltration did not
correlate with other variables tested, including grade, metastases,
vascular invasion and tumour size. In NETLMs, higher-grade
tumours were more likely to demonstrate high levels of infiltra-
tion by Treg. A correlation between tumour grade and Treg infil-
tration has been reported in primary hepatic neoplasms.26
When all patients with NETs were analysed, the degree of T cell
infiltration did not correlate with recurrence. In recognition of
the distinct biologic behaviour of low- and intermediate-grade
NETs,10 we analysed these subgroups separately, as the challenge is
to identify those with intermediate-grade tumours who will do
poorly. It is reasonable to speculate that the immunologic and
biologic impact of infiltrating T cells would be more important in
inherently aggressive tumours. The rarity of NETs and the pro-
tracted recurrence-free intervals in patients with low-grade NETs
are likely to render the impact of infiltrating T cells imperceptible
or irrelevant (Fig. 2). However, in patients with intermediate-
grade primary NETs and NETLMs, T cell infiltrates were signifi-
cant predictors of outcome (Figs 3 and 4). Whether the TILs
directly affect tumour progression and patient outcome or simply
represent another surrogate of tumour biology remains to be
determined. It is important to note that TIL counts were not
independent predictors of outcome on multivariate analyses. Our
Table 4 Predictors of recurrence-free survival in intermediate-grade neuroendocrine tumours
Variables Median RFS,
months
P-value Multivariate RR
(95% CI), P-value
Tumour sizea
4.2 cm 72 0.07 –
<4.2 cm 130
Lymph node metastasesb
Present 61 0.02 0.11
Absent 128
Vascular invasion
Present 67 0.02 0.95
Absent 130
Surgical margin
Positive 67 0.10 –
Negative 128
CD3
High 128 0.05 0.23
Low 61
CD8
High 128 0.27 –
Low 61
CD4
High 106 0.19 –
Low 60
FoxP3
High 106 0.65 –
Low 72
aMedian tumour size was 4.2 cm
bOnly patients who underwent lymph node sampling were included
RFS, recurrence-free survival; RR, relative risk; 95% CI, 95% confidence interval
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small sample size may account for the lack of independent statis-
tical significance in analyses of CD3+ TILs in NETs and FoxP3+
TILs in NETLMs.
Although CD3 and FoxP3 immunoreactivity may represent
novel predictors of outcome in patients with NETs and NETLMs,
the potential clinical utility of our findings may relate to the ability
to identify novel immunotherapeutic targets for patients with
biologically aggressive disease. A detailed understanding of NET T
cells may allow the application of immunomodulatory therapy in
patients with more aggressive primary lesions or metastatic
disease. For example, if a low level of T cell infiltration is associ-
ated with earlier recurrence of disease, then stimulation of the
immune system to increase the anti-tumour T cell response may
result in clinical benefit in selected patients with NETs. Likewise,
targeted therapy designed to limit the suppressive influence of
Treg may be of interest in the management of NETLMs.
Patients with NETLMs from different primary sites were analy-
sed as a single group as a result of previous reports indicating that
outcomes in patients with metastatic liver disease are not depen-
dent on the original disease site.8 Our finding that CD3+ cell
counts predicted outcome in NETs and not in NETLMs most
likely reflects different T cell subset proportions in the different
sites. A more prominent role for FoxP3+ cells, which also express
CD3, in liver tumours may diminish the positive influence of the
overall CD3+ infiltrate. Thus, a greater number of CD3+ cells
within NETLMs may confer both favourable and unfavourable
biologic effects. Another factor which may affect disparate
immune response to primary and metastatic NETs is that patients
with liver metastases received additional treatment, including
somatostatin and embolization.
Several limitations of these data warrant consideration. The
demonstration of T cells within a tumour and a correlation
between T cell number and outcome do not definitively prove
physiologic relevance. Although the presence of TILs in NETs and
NETLMs may represent an epiphenomenon to an unmeasured
biologic event, we speculate that an anti-tumour response is asso-
ciated with improved outcome. Our finding that a higher CD3+
infiltrate among those with intermediate-grade NETs implied less
likelihood of recurrence suggests that an immune response
confers some advantage. The correlation of higher FoxP3+ cells or
Treg with decreased survival following presentation with
NETLMs raises the possibility that suppression of the intrahepatic
immune response negatively impacts survival. These data resonate
well with our current understanding of the immune response to
other primary and metastatic tumours.
Another limitation of the current paper is that the utilization of
single-marker staining with immunohistochemistry does not
allow for the precise cellular characterization achieved with multi-
marker flow cytometry. Although immune cells are best identified
with a constellation of cell surface markers, we have previously
shown that the single-marker immunohistochemistry technique
is >70% accurate for identification of T cell subsets.20 The TIL
score selected for each T cell marker to distinguish the low and
Figure 3 Low- and intermediate-grade neuroendocrine tumours
(NETs) were stained with anti-CD3 to quantify the numbers of various
T cell subsets within the tumours. Kaplan–Meier analyses were per-
formed to determine differences in recurrence-free survival among
patients with high and low levels of T cell infiltration. Thirteen
patients without documented grade information were excluded from
this analysis
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Figure 4 Neuroendocrine tumour liver metastases (NETLMs) were
stained with anti-FoxP3 to quantify the numbers of regulatory T cells
within the tumours. Kaplan–Meier analyses were performed to deter-
mine differences in overall survival among patients with high and low
levels of T cell infiltration
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high groups was chosen based upon the median value. Other
cut-off values or other scoring systems may also yield statistically
significant prognostic data. Whether the methods proposed in this
study are optimal will require additional validation. Finally, only a
minority of patients with NETLMs received chemotherapy (n =
10) or somatostatin treatment (n = 11). Although we did not find
any significant associations between these treatments and TIL
counts or outcome, we cannot discount the potential influence of
systemic or regional therapy in the immune response to NETLMs.
We have demonstrated that the level of NET T cell infiltration is
predictive of RFS in intermediate-grade NETs and NETLMs on
univariate analysis. Whether TIL analysis in NETs and NETLMs is
a clinically useful marker for risk stratification will require further
validation. Although we have not demonstrated TIL counts to be
an independent prognostic factor in patients with NETs and
NETLMs, the data are suggestive of the biologic importance of the
host immune response to neuroendocrine neoplasms.
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